Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 163-167 , April 2010

Hodgkin’s lymphoma in the young child

References 

  1. SEER Cancer Statistics Review 2001–2005. Hodgkin lymphoma fact sheet. Surveillance epidemiology and end results (SEER), http://seer.cancer.gov/csr/1975_2005/results_single/sect_09_table.04.pdf; 2008 [accessed 11.12.08].
  2. Clavel J, Steliarova-Foucher E, Berger C, Danon S, Valerianova Z. Hodgkin’s disease incidence and survival in European children and adolescents (1978–1997): report from the automated cancer information system project. Eur J Cancer. 2006;42(13):2037–2049
  3. Gruffermann S, Delzell E. Epidemiology of Hodgkin disease. Epidemiol Rev. 1984;6:76–106
  4. Stiller CA, Parkin DM. International variations in the incidence of childhood lymphomas. Paediatr Perinat Epidemiol. 1990;4(3):303–324
  5. Parkin DM, Stiller CA, Draper GJ, Bieber CA. The international incidence of childhood cancer. Int J Cancer. 1988;42:511–520
  6. Yadav MS, Malinga N, Ablashi DV. Development of immunity to Epstein-Barr virus in Malaysian children. Microbiologica. 1987;10:29–35
  7. Chan CW, Chiang AKS, Chan KH, Lau ASY. Epstein-Barr virus-associated infectious mononucleosis in Chinese children. Pediatr Infect Dis J. 2003;22:974–978
  8. Hjalgrim H, Smedby KE, Rostgaard K, Molin D, Hamilton-Dutoit S, Chang ET, et al. Infectious mononucleosis, childhood social environment and risk of Hodgkin lymphoma. Cancer Res. 2007;67(5):2382–2388
  9. Weinreb M, Day PJR, Niggli F, Green EK, Nyong’o AO, Othieno-Abinya NA, et al. The consistent association between Epstein-Barr virus and Hodgkin’s disease in children in Kenya. Blood. 1996;87(9):3828–3836
  10. De Matteo E, Baron AV, Chabay P, Porta J, Dragosky M, Preciado MV. Comparison of Epstein-Barr virus presence in Hodgkin lymphoma in pediatric versus adult Argentine patients. Arch Pathol Lab Med. 2003;127:1325–1329
  11. Chang K-C, Nguyen TK, Jone D, Su I-J. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special empahsis on the entity of lymphocyte predominance subtype. Hum Pathol. 2005;36:747–755
  12. Liu S-M, Chow K-C, Chiu C-F, Tzeng C-H. Expression of Epstein-Barr virus in patients with Hodgkin’s disease in Taiwan. Cancer. 1998;83:367–371
  13. Zhou XG, Sandvej K, Li PJ, Ji XL, Yan QH, Zhang XP, et al. Epstein-Barr virus in Chinese pediatric Hodgkin disease. Cancer. 2001;92:1621–1631
  14. Belgaumi AF, Al-Kofide AA, Joseph N, Jmail-Malik R, Khafaga Y, Sabbah R. Hodgkin lymphoma in very young children: clinical characteristics and outcome of treatment. Leuk Lymphoma. 2008;49(5):910–916
  15. Donaldson SS, Hudson MM, Lamborn KR, Link MP, Kun L, Billet AL, et al. VAMP and low-dose, involved field radiation for children and adolescents with favorable, early-stage Hodgkin’s disease: results of a prospective clinical trial. J Clin Oncol. 2002;20(14):3081–3087
  16. Nachman JB, Sposto R, Herzog P, Gilchrist GS, Wolden SL, Thomson J, et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin’s disease who achieve a complete response to chemotherapy. J Clin Oncol. 2002;20(18):3765–3771
  17. Nachman JB. Radiation therapy in pediatric Hodgkin disease – who needs it?. Ann Oncol. 2008;19(Suppl. 4):iv108
  18. Straus David J, Portlock Carol S, Qin Jing, Myers Jane, Zelenetz Andrew D, Moskowitz Craig, et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood. 2004;104(12):3483–3489
  19. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C, et al. ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin’s lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol. 2005;23(36):9198–9207
  20. Horning SJ, Hoppe RT, Breslin S, Bartlett NL, Brown W, Rosenburg SA. Stanford V and radiotherapy for locally extensive and advanced Hodgkin’s disease: mature results of a prospective clinical trial. J Clin Oncol. 2002;20(3):630–637
  21. Ruhl U, Albrecht M, Dieckmann K, Luders H, Marciniak H, Schellenberg D, et al. Response-adapted radiotherapy in the treatment of pediatric Hodgkin’s disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiation Oncol Biol Phys. 2001;51(5):1209–1218
  22. Weiner MA, Leventhal B, Brecher ML, Marcus RB, Cantor A, Gieser PW, et al. Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB and IV Hodgkin’s disease in pediatric patients: a pediatric oncology group study. J Clin Oncol. 1997;15(8):2769–2779
  23. Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SA, et al. Feasibility and upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin’s lymphoma: preliminary results from the children’s cancer group study CCG 59704. Ann Oncol. 2002;13(Suppl 1):107–111
  24. Stoneham S, Ashley S, Pinkerton R, Hewitt M, Wallace WH, Shankar AG. Hodgkin’s lymphoma in children aged 5 years or less – the United Kingdom experience. Eur J Cancer. 2007;43(9):1415–1421

PII: S1473-0502(10)00014-5

doi: 10.1016/j.transci.2010.01.013

Transfusion and Apheresis Science
Volume 42, Issue 2 , Pages 163-167 , April 2010

Article Tools

* Image Usage & Resolution